Continued treatment with antiplatelet medications but not aspirin reduced risk of bleeding
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the P2Y12 inhibitor clopidogrel fared significantly better after one year compared with those who followed the standard practice of continuing both medications, according to recent research. Stopping aspirin early was found to be superior in terms of the trial’s primary endpoint, a composite of death from cardiovascular causes, heart attack, clotting near the stent, stroke and major bleeding.
“According to the findings, one-month DAPT followed by clopidogrel monotherapy could be a good option after drug-eluting stent implantation with the advantage of fewer bleeding events”.
To know more about Cardiovascular updates join us in Italy at Cardiology Congress 2019.
No comments:
Post a Comment